Navigation Links
Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Date:6/14/2013

any time.     

Mr. Richard T. Schumacher, President and CEO of PBI, said: "During the conference call after the release of our strong 2013 first quarter financial results, we discussed the importance of developing a clear and attainable path to financial strength, and the need to start that plan as soon as possible. With the Series J and $500,000 Note closings, we believe we have successfully achieved the initial objectives of our plan."

Mr. Schumacher continued: "Our next goal is to greatly strengthen our cash position before year-end.  We believe this will enable us to take full advantage of the significant breakthroughs we have recently announced in our patented pressure cycling technology ("PCT") platform, as well as to continue to expand our customer base through sales of our existing and enabling PCT product line. We plan to achieve this goal through a combination of financings, continued reductions in costs, and measurable increases in revenue.  We believe we are already well on our way to achieving this goal."

About the Series J Private Placement and Note

The units of Series J Preferred Stock and Warrants and the Note were issued only to accredited investors in private placements without registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance upon the exemption from registration set forth in Rule 506 of Regulation D promulgated under the Securities Act.  This press release is not an offer to sell or a solicitation of offers to buy the units or shares of Series J Preferred Stock, shares of Common Stock, Warrants or Notes. The units, shares of Series J Preferred Stock, shares of Common Stock, Warrants and Notes have not been registered under the Securities Act and may not be sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
2. High pressure gold nanocrystal structure revealed
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
5. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
6. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
10. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
11. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Carolina (PRWEB) May 01, 2015 Spirax ... services, is extremely proud to announce that for the ... named as a winner of a Queen’s Award for ... for the design and manufacture of a unique flowmeter. ... the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... 30, 2015   Tamir Biotechnology , a leading ... on its Ebola antiviral therapy program. ... is currently being evaluated and considered by a number ... Ebola. During the first quarter of 2015, the company ... Accelerate The Evaluation of Potential Treatments and Vaccines For ...
(Date:4/30/2015)... MINNEAPOLIS, MN , April 30, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has commenced ... addition, BioAmber expects to grant the underwriters a 30-day ... of the shares of common stock offered in the ... and there can be no assurance as to whether ...
(Date:4/30/2015)... 2015 Oxford Finance LLC ("Oxford"), a specialty ... and healthcare services companies, today announced the closing of ... Celula, Inc., a diagnostic testing company focused on improving ... care and improved outcomes.  Proceeds of the loan will ... commercialization of its products in the U.S. and ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Oxford Finance Provides $10 Million Debt Financing to Celula 2
... Sept. 18 Caliper Life,Sciences, Inc. (Nasdaq: ... the,UBS Global Life Sciences Conference in New York ... at 3:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The audio-only webcast can be accessed ...
... /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... therapeutics, today announced that ARIUS Research Inc.,shareholders and ... the Company and Roche., At a special ... ARIUS,shareholders and warrant holders approved the transaction, with ...
... MADISON, Wis., Sept. 18 Cellectar, Inc., a,privately-held ... treat and monitor human cancers, today announced the,appointment ... Board of,Directors., Mr. Harwood, 55, is a ... private equity firm. Prior to working with Avista,Mr. ...
Cached Biology Technology:ARIUS sale approved by shareholders 2Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... A class of Alzheimer,s disease drugs currently studied ... traumatic brain injury in animals, researchers at Georgetown University ... of Nature Medicine . They say the ... do something no other drug has been able to ...
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... consumption are undisputable, although some data suggest that ... For instance, several studies have reported a positive ... (BMD) in older women. There are fewer studies ... and none have considered different classes of alcoholic ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Iron is involved in prion disease-associated neuronal demise 2
MOUSE ANTI BOVINE CD335:ALEXA 488 Immunogen: Fusion protein consisting of the extracellular region of bovine CD335....
... Kit is intended for the derivation ... blastocysts in serum-free conditions. ... Clonal Grade Medium Basal Medium ... Trypsin Solution Gelatin Solution Complete ...
RABBIT ANTI TRANSFERRIN RECEPTOR...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Biology Products: